These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 12792873

  • 1. Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?
    Armijos RX, Weigel MM, Romero L, Garcia V, Salazar J.
    J Infect Dis; 2003 Jun 15; 187(12):1959-61. PubMed ID: 12792873
    [Abstract] [Full Text] [Related]

  • 2. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.
    Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J.
    Vaccine; 2004 Mar 12; 22(9-10):1320-6. PubMed ID: 15003662
    [Abstract] [Full Text] [Related]

  • 3. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.
    Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, Momeni AZ, Dowlati Y, Godal T, Zicker F, Smith PG, Modabber F.
    Lancet; 1998 May 23; 351(9115):1540-3. PubMed ID: 10326536
    [Abstract] [Full Text] [Related]

  • 4. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up.
    Armijos RX, Weigel MM, Aviles H, Maldonado R, Racines J.
    J Infect Dis; 1998 May 23; 177(5):1352-7. PubMed ID: 9593024
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of an autoclaved Leishmania major vaccine.
    Khalil EA, Elhassan AM, Zijlstra EE, Osman OF, Eljack IA, Ibrahim ME, Mukhtar MM, Ghalib HW, Modabbers F.
    East Afr Med J; 2000 Sep 22; 77(9):468-70. PubMed ID: 12862135
    [Abstract] [Full Text] [Related]

  • 9. Progress towards a Leishmania vaccine.
    Tabbara KS.
    Saudi Med J; 2006 Jul 22; 27(7):942-50. PubMed ID: 16830009
    [Abstract] [Full Text] [Related]

  • 10. Second-generation vaccines against leishmaniasis.
    Coler RN, Reed SG.
    Trends Parasitol; 2005 May 22; 21(5):244-9. PubMed ID: 15837614
    [Abstract] [Full Text] [Related]

  • 11. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y, Jones DE.
    Ann N Y Acad Sci; 2004 Oct 22; 1026():267-72. PubMed ID: 15604504
    [Abstract] [Full Text] [Related]

  • 12. Development of a leishmaniasis vaccine: the importance of MPL.
    Reed SG, Coler RN, Campos-Neto A.
    Expert Rev Vaccines; 2003 Apr 22; 2(2):239-52. PubMed ID: 12899575
    [Abstract] [Full Text] [Related]

  • 13. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis.
    Haile M, Schröder U, Hamasur B, Pawlowski A, Jaxmar T, Källenius G, Svenson SB.
    Vaccine; 2004 Mar 29; 22(11-12):1498-508. PubMed ID: 15063575
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis.
    Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F, Sharifi I, Khalil EA, Bernal ID, Antunes CM, Smith PG.
    Vaccine; 2009 Jul 30; 27(35):4747-53. PubMed ID: 19540273
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug 30; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
    Calvopina M, Barroso PA, Marco JD, Korenaga M, Cooper PJ, Nonaka S, Hashiguchi Y.
    Vaccine; 2006 Jul 07; 24(27-28):5645-52. PubMed ID: 16621179
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advances in battle against leishmaniasis.
    TDR News; 1998 Oct 07; (57):2. PubMed ID: 12294756
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT, Vale AM, França da Silva JC, da Costa RT, Quetz Jda S, Martins Filho OA, Reis AB, Corrêa Oliveira R, Machado-Coelho GL, Bueno LL, Bethony JM, Frank G, Nascimento E, Genaro O, Mayrink W, Reed S, Campos-Neto A.
    Vet Res; 2005 Oct 07; 36(5-6):827-38. PubMed ID: 16120256
    [Abstract] [Full Text] [Related]

  • 20. Current status and perspectives of the immunotherapy of leishmaniasis.
    El-On J.
    Isr Med Assoc J; 2009 Oct 07; 11(10):623-8. PubMed ID: 20077951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.